Abstract
The considerable success of vaccination against the new coronavirus infection, which has led to a decrease in morbidity and mortality in adults and children, requires the study of the problem of revaccination against SARS-CoV-2. The pathogenic properties of the virus and its unpredictable mutations continue to support an unfavorable epidemic situation in different regions of the world. Revaccination regimens against SARS-CoV-2 are being developed in different countries and populations based on epidemiological indications. The issue of introducing vaccination against a new coronavirus infection into national vaccination calendars for adults and children is debatable and requires further study.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
